Skip to main content

Table 2 Prognostic evaluation of clinicopathological parameters for cancer-specific survival in 97 renal cell carcinomas by univariate and multivariate analyses

From: A risk stratification model based on four novel biomarkers predicts prognosis for patients with renal cell carcinoma

  Univariate Multivariate
  n HR
(95% CI)
p value† HR
(95% CI)
p value†
Sex
(male/female)
77/20 0.85
(0.24–3.02)
0.807   
Age, years
(> 62 vs ≤ 62)
52/45 0.75
(0.27–2.04)
0.569   
Histological subtype
(non-clear vs clear)
21/76 1.30
(0.36–4.75)
0.690   
T classification
(3,4 vs 1,2)
25/72 8.76
(2.90–26.42)
< 0.001 12.00
(1.50–96.30)
0.019
Vascular invasion
(yes vs no)
67/30 36.65
(0.41–3276)
0.116   
Pathological grade
(3 vs 1,2)
18/79 12.83
(3.93–41.91)
< 0.001 2.13
(0.42–10.70)
0.358
Nephrectomy
(radical vs partial)
51/46 10.27
(1.32–80.06)
0.026 2.24
(0.24–20.94)
0.480
Metastasis at diagnosis
(yes vs no)
27/70 23.31
(5.23–103.8)
< 0.001 9.17
(1.45–57.83)
0.018
ARL4C expression
(high vs low)
26/71 10.57
(3.62–30.89)
< 0.001 10.98
(1.77–68.02)
0.010
ECT2 expression
(high vs low)
28/69 3.06
(1.11–8.39)
0.030 1.14
(0.06-20.67)
0.928
SOD2 expression
(high vs low)
26/71 3.98
(1.43–11.07)
0.008 4.01
(0.24–68.31)
0.337
STEAP3 expression
(high vs low)
10/87 10.08
(3.25–31.25)
< 0.001 0.16
(0.02–1.51)
0.109
  1. †Cox proportional hazards regression models
  2. HR hazard ratio, CI confidence interval